The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans

키워드

참고문헌 (50)

1. "Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents"[URL]
2. Aberg JA, "Primary care guidelines for the management of persons infected with human immunodeficiency virus:2009 update by the HIV medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 49, pp.651~681 (2009)
3. "European Guidelines for treatment of HIV-infected adults in Europe v7.1"[URL]
4. Hirsch MS, "Antiretroviral drug resistance testing in adult HIV-1 infection:2008 recommendations of an International AIDS Society-USA panel", Clin Infect Dis, 47, pp.266~285 (2008)
5. Mallal S, "HLA-B*5701 screening for hypersensitivity to abacavir", N Engl J Med, 358, pp.568~579 (2008)
6. Kitahata MM, "Effect of early versus deferred antiretroviral therapy for HIV on survival", N Engl J Med, 360, pp.1815~1826 (2009)
7. Grinsztejn B, "Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial", Lancet Infect Dis, 14, pp.281~290 (2014)
8. Cohen MS, "Prevention of HIV-1 infection with early antiretroviral therapy", N Engl J Med, 365, pp.493~505 (2011)
9. Hargrove JW, "Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe", AIDS, 24, pp.F11~F14 (2010)
10. Kalayjian RC, "Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease", AIDS, 22, pp.481~487 (2008)
11. Thio CL, "HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)", Lancet, 360, pp.1921~1926 (2002)
12. Matthews GV, "A randomized trial of combination hepatitis B therapy in HIV", HBV coinfected antiretroviral naive individuals in Thailand, 2008, pp.48, 1062~1069
13. Peters MG, "Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection:ACTG A5127", Hepatology, 44, pp.1110~1116 (2006)
14. Egger M, "Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies", Lancet, 360, pp.119~129 (2002)
15. Gianella S, "Effect of early antiretroviral therapy during primary HIV-1infection on cell-associated HIV-1 DNA and plasma HIV-1RNA", Antivir Ther, 16, pp.535~545 (2011)
16. Wyl V, "Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption", PLoS One, 6 (2011)
17. Sax PE, "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy", N Engl J Med, 361, pp.2230~2240 (2009)
18. Smith KY, "Randomized, double-blind, placebo-matched, multicenter trial of abacavir", lamivudine or tenofovir, ritonavir for initial HIV treatment, pp.AIDS, 2009[DOI]
19. Arribas JR, "Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine", lamivudine and efavirenz in treatment-naive patients: 144-week analysis, 2008, pp.47, 74~78
20. Berenguer J, "Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903", Clin Infect Dis, 47, pp.1083~1092 (2008)
21. Orkin C, "Final 192-week efficacy and safety of once-daily darunavir", ritonavir compared with lopinavir, HIV Med, pp.2013, 14[DOI]
22. Molina JM, "Once-daily atazanavir", ritonavir compared with twice-daily lopinavir, J Acquir Immune Defic Syndr, pp.2010, 53[DOI]
23. Riddler SA, "Class-sparing regimens for initial treatment of HIV-1 infection", N Engl J Med, 358, pp.2095~2106 (2008)
24. Malan DR, "Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients", J Acquir Immune Defic Syndr, 47, pp.161~167 (2008)
25. Molina JM, "Week 96analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies", mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials, 2014, pp.15, 57~62
26. Rockstroh JK, "Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir", emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK, 2013, pp.63, 77~85
27. DeJesus E, "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial", Lancet, 379, pp.2429~2438 (2012)
28. Ledergerber B, "Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes", Lancet, 364, pp.51~62 (2004)
29. Matthews GV, "Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV", HBV coinfected individuals, 2009, pp.23, 1707~1715
30. de Vries-Sluijs TE, "Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus", Gastroenterology, 139, pp.1934~1941 (2010)
31. Pessôa MG, "Efficacy and safety of entecavir for chronic HBV in HIV", HBV coinfected patients receiving lamivudine as part of antiretroviral therapy, 2008, pp.22, 1779~1787
32. Benhamou Y, "Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study", Lancet, 358, pp.718~723 (2001)
33. Ingiliz P, "Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients", Antivir Ther, 13, pp.895~900 (2008)
34. McMahon MA, "The HBV drug entecavir -effects on HIV-1 replication and resistance", N Engl J Med, 356, pp.2614~2621 (2007)
35. Dore GJ, "Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption", AIDS, 24, pp.857~865 (2010)
36. Ge D, "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance", Nature, 461, pp.399~401 (2009)
37. Thomas DL, "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus", Nature, 461, pp.798~801 (2009)
38. Rauch A, "Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study", Gastroenterology, 138, pp.1338~1345 (2010)
39. Ghany MG, "Progression of fibrosis in chronic hepatitis C", Gastroenterology, 124, pp.97~104 (2003)
40. Macías J, "Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus", hepatitis C virus, 2009, pp.50, 1056~1063
41. Verma S, "Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?", BMC Res Notes, 1, pp.46~ (2008)
42. Ragni MV, "Highly active antiretroviral therapy improves ESLD-free survival in HIVHCV co-infection", Haemophilia, 15, pp.552~558 (2009)
43. Alvarez D, "Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons", J Viral Hepat, 13, pp.683~689 (2006)
44. Vispo E, "Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir", Antivir Ther, 13, pp.429~437 (2008)
45. Laufer N, "Abacavir does not influence the rate of virological response in HIV-HCVcoinfected patients treated with pegylated interferon and weight-adjusted ribavirin", Antivir Ther, 13, pp.953~957 (2008)
46. Mira JA, "Efficacy of pegylated interferon plus ribavirin treatment in HIV", hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone, 2008, pp.62, 1365~1373
47. Aranzabal L, "Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection", Clin Infect Dis, 40, pp.588~593 (2005)
48. Núñez M, "Hepatotoxicity of antiretrovirals: incidence, mechanisms and management", J Hepatol, 44(1 Suppl), pp.S132~S139 (2006)
49. McGovern BH, "Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients", Clin Infect Dis, 43, pp.365~372 (2006)
50. Tubiana R, "Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500copies", ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1), 2010, pp.50, 585~596

관련 논문AI추천